Ipca Laboratories, a leading pharmaceutical company, has reported its financial results for the fourth quarter (Q4FY24) and the full fiscal year 2024 (FY24).
Q4FY24 Financial Highlights (Consolidated):
Net Total Income: Up 33% at ₹2,051.93 crore
EBITDA Margin: (Before forex (gain)/loss, other income, and exceptional items) 14.98% in Q4FY24 compared to 11.29% in Q4FY23
Net Profit (after exceptional items): ₹59.59 crore, down 22% YoY
FY24 Financial Highlights (Consolidated):
Net Total Income: Up 23% at ₹7,829.81 crore
Indian Formulations Income: Up 12% at ₹3,097.16 crore
Exports Income: Up 2% at ₹2,707.70 crore
Net Profit (after exceptional items): ₹530.41 crore, up 5% YoY
Key Takeaways:
Revenue Growth: Ipca Laboratories experienced strong revenue growth in both Q4FY24 and FY24, driven by increased sales in both domestic and international markets.
Improved Margins: The company's EBITDA margin improved significantly in Q4FY24 and FY24, indicating better operational efficiency.
Profit Decline in Q4: Net profit declined in Q4FY24 due to exceptional items, but the overall FY24 performance remained positive.
Strong Growth in Indian Formulations: The company's Indian formulations business continued to show robust growth, contributing to the overall revenue increase.
For further analysis and information, you can refer to the following resources:
Ipca Laboratories Ltd. Investor Relations: https://www.ipca.com/investors-annual-reports/
ICICI Direct Analysis: [invalid URL removed]
5paisa Share Price: https://www.5paisa.com/stocks/ipcalab-share-price
Comments